welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
WVE-210201 safety and tolerability profile supports Phase 2/3 clinical trial initiation in boys with DMD amenable to exon 51 skipping Delivery of interim efficacy data from ongoing open-label extension study expected in H2 2019 CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial. Based on results from four ascending dose cohorts in the Phase 1 trial and pending final analysis, Wave has selected a dose for its planned Phase 2/3 clinical trial of WVE-210201, which it intends to initiate in 2019. In parallel, the independent Safety Monitoring Committee of the Phase 1 clinical trial has endorsed moving forward with a higher dose of WVE-210201 to be studied in a fifth cohort. Wave plans to present the results from the WVE-210201 Phase 1 clinical trial, as well as details of the Phase 2/3 study design, at upcoming scientific meetings.
rareRelated
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
-
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
-
Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)...Antisense oligonucleotides (AONs) in cli...
-
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051The U.S. Food and Drug Administration ha...
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug ApplicationOn February 14, 2019, Sarepta Therapeuti...